Contineum Therapeutics (CTNM) Earnings Date & Reports

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

CTNM is expected to report earnings to fall 54.84% to -28 cents per share on August 19

Contineum Therapeutics CTNM Stock Earnings Reports

Q2'25

Est.

$-0.28

Q1'25

Missed

by $0.20

Q4'24

Missed

by $0.11

Q3'24

Missed

by $0.04

Q2'24

Missed

by $0.03

The last earnings report on May 15 showed earnings per share of -62 cents, missing the estimate of -41 cents. With 145.16K shares outstanding, the current market capitalization sits at 114.61M.

View a ticker or compare two or three

Compare

CTNM